Cargando…
A new day, a new treatment. A case report
INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic famil...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568230/ http://dx.doi.org/10.1192/j.eurpsy.2022.1870 |
_version_ | 1784809596581314560 |
---|---|
author | Galerón, R. Serván, B. Huete Naval, M. Herrero Pellón, E. Albarracin, P. |
author_facet | Galerón, R. Serván, B. Huete Naval, M. Herrero Pellón, E. Albarracin, P. |
author_sort | Galerón, R. |
collection | PubMed |
description | INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic family situation, the patient starts to show suspicious, with insomnia and a progressive social isolation. Despite an attempt of ambulatory treatment with oral aripiprazole, showing good tolerance, the patient refuses such treatment, showing active clinical psychotic with great distress and behavioral repercussion, finally requiring hospital admission. OBJECTIVES: To perform a literature review about the treatment initiation with two vials of aripiprazole long-acting injection. METHODS: Literature review of scientific articles using Pubmed as search engine. We considered articles published both in English and Spanish. RESULTS: During hospital stay, treatment with 2 intramuscular injections of 400mg of aripiprazole is started, combined with a single dose of oral aripiprazole 20mg on day 1, assuring correct dosing, with good tolerance and favoring therapeutic adherence. Progressively, the patient starts to feel calmer, adequate, collaborative and emotionally stable, recuperating chronobiological rhythms, with remission of the hallucinations and appearing more distant from delusions. CONCLUSIONS: According to the currently available studies, the use of this posology could avoid the potential impact that lack of adherence to oral treatment could have in the therapeutic outcome, assuring a correct dosing and favoring adherence from day 1. Furthermore, this would help simplify the medication regiment for patients, physicians and caregivers. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9568230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95682302022-10-17 A new day, a new treatment. A case report Galerón, R. Serván, B. Huete Naval, M. Herrero Pellón, E. Albarracin, P. Eur Psychiatry Abstract INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic family situation, the patient starts to show suspicious, with insomnia and a progressive social isolation. Despite an attempt of ambulatory treatment with oral aripiprazole, showing good tolerance, the patient refuses such treatment, showing active clinical psychotic with great distress and behavioral repercussion, finally requiring hospital admission. OBJECTIVES: To perform a literature review about the treatment initiation with two vials of aripiprazole long-acting injection. METHODS: Literature review of scientific articles using Pubmed as search engine. We considered articles published both in English and Spanish. RESULTS: During hospital stay, treatment with 2 intramuscular injections of 400mg of aripiprazole is started, combined with a single dose of oral aripiprazole 20mg on day 1, assuring correct dosing, with good tolerance and favoring therapeutic adherence. Progressively, the patient starts to feel calmer, adequate, collaborative and emotionally stable, recuperating chronobiological rhythms, with remission of the hallucinations and appearing more distant from delusions. CONCLUSIONS: According to the currently available studies, the use of this posology could avoid the potential impact that lack of adherence to oral treatment could have in the therapeutic outcome, assuring a correct dosing and favoring adherence from day 1. Furthermore, this would help simplify the medication regiment for patients, physicians and caregivers. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9568230/ http://dx.doi.org/10.1192/j.eurpsy.2022.1870 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Galerón, R. Serván, B. Huete Naval, M. Herrero Pellón, E. Albarracin, P. A new day, a new treatment. A case report |
title | A new day, a new treatment. A case report |
title_full | A new day, a new treatment. A case report |
title_fullStr | A new day, a new treatment. A case report |
title_full_unstemmed | A new day, a new treatment. A case report |
title_short | A new day, a new treatment. A case report |
title_sort | new day, a new treatment. a case report |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568230/ http://dx.doi.org/10.1192/j.eurpsy.2022.1870 |
work_keys_str_mv | AT galeronr anewdayanewtreatmentacasereport AT servanb anewdayanewtreatmentacasereport AT huetenavalm anewdayanewtreatmentacasereport AT herreropellone anewdayanewtreatmentacasereport AT albarracinp anewdayanewtreatmentacasereport AT galeronr newdayanewtreatmentacasereport AT servanb newdayanewtreatmentacasereport AT huetenavalm newdayanewtreatmentacasereport AT herreropellone newdayanewtreatmentacasereport AT albarracinp newdayanewtreatmentacasereport |